Tenaya Therapeutics
TNYA
103 hedge funds and large institutions have $37.5M invested in Tenaya Therapeutics in 2026 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 19 closing their positions.
750% more call options, than puts
Call options by funds: $408K | Put options by funds: $48K
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
37% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 19
6% more funds holding
Funds holding: 97 → 103 (+6)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
16.2% less ownership
Funds ownership: 41.22% → 25.03% (-16%)
23% less capital invested
Capital invested by funds: $48.8M → $37.5M (-$11.3M)
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$1.37M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$959K |
| 3 |
Millennium Management
New York
|
+$621K |
| 4 |
Jane Street
New York
|
+$370K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$271K |
Top Sellers
| 1 |
CG
Column Group
San Francisco,
California
|
-$6.69M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$2.95M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.85M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.07M |
| 5 |
EAM
Empery Asset Management
New York
|
-$832K |
TNYA Hedge Fund Activity: Q1 2026 in Review
103 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Tenaya Therapeutics (TNYA) for Q1 2026, worth a combined $37.5M — down 23% from $48.8M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TNYA positions and 19 closed out — a net gain of 7 holders — while 32 added to existing stakes and 18 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.37M. The largest seller was Column Group, exiting entirely with an estimated $6.69M sold.
- 103 institutional investors held Tenaya Therapeutics (TNYA) as of Q1 2026, up from 97 in Q4 2025.
- Funds reported $37.5M of Tenaya Therapeutics stock for Q1 2026, down 23% quarter-over-quarter.
- 26 funds opened new Tenaya Therapeutics positions in Q1 2026 and 19 closed out, a net change of +7 holders.
- The largest Tenaya Therapeutics buyer in Q1 2026 was Renaissance Technologies, an estimated $1.37M added.
- The largest Tenaya Therapeutics seller in Q1 2026 was Column Group, an estimated $6.69M sold.
Based on aggregated 13F filings for Q1 2026.